Bladder Cancer

Clinical data, expert insights, and treatment advancements presented at the ASCO Genitourinary Cancers Symposium bladder cancer sessions, focusing on practice-informing updates.

Bladder, Kidney, and Prostate Cancer Highlights From ASCO GU 2026

Petros Grivas, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASCO GU 2026: Key Updates in Bladder, Prostate, and Kidney Cancer

Charbel Matar, MD

Novel HER2–Targeting Therapies in Urothelial Cancer

Miles Hsu, MD, Brendan Guercio, MD

Circulating Tumor DNA to Guide Treatment in Muscle-Invasive Bladder Cancer

Brendan Guercio, MD, Andrea Apolo, MD

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer in KEYNOTE-B15/EV-304

Rahul Gosain, MD, MBA, Rohit Gosain, MD

Enfortumab Vedotin-Pembrolizumab’s Role in Muscle-Invasive Bladder Cancer Treatment

Elias Chandran, MBBS, FRACP, Vishesh Khanna, MD

Insights from ASCO GU 2026: Evolving Treatment Strategies in Bladder Cancer

Zeynep Irem Ozay, MD

Immunotherapy Plus BCG Shows Promise in NMIBC: Insights From POTOMAC and CREST

Ashish M. Kamat, MD, MBBS, FACS, Vishesh Khanna, MD